ANTONIOLI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.546
EU - Europa 3.532
AS - Asia 1.593
SA - Sud America 185
AF - Africa 55
Continente sconosciuto - Info sul continente non disponibili 55
OC - Oceania 31
Totale 9.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.485
PL - Polonia 1.174
RU - Federazione Russa 831
IT - Italia 627
SG - Singapore 430
CN - Cina 354
HK - Hong Kong 285
SE - Svezia 234
IE - Irlanda 193
VN - Vietnam 155
BR - Brasile 149
KR - Corea 135
DE - Germania 117
FI - Finlandia 84
FR - Francia 77
UA - Ucraina 73
IN - India 60
GB - Regno Unito 55
CA - Canada 38
BD - Bangladesh 35
CH - Svizzera 32
AU - Australia 30
JO - Giordania 29
TR - Turchia 23
ID - Indonesia 15
JP - Giappone 13
EC - Ecuador 12
AR - Argentina 11
CI - Costa d'Avorio 11
IQ - Iraq 10
NL - Olanda 10
BE - Belgio 9
MX - Messico 9
ZA - Sudafrica 9
NG - Nigeria 8
ES - Italia 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
PH - Filippine 5
PK - Pakistan 5
SA - Arabia Saudita 5
DZ - Algeria 4
IL - Israele 4
KE - Kenya 4
PY - Paraguay 4
AZ - Azerbaigian 3
CO - Colombia 3
EG - Egitto 3
ET - Etiopia 3
HN - Honduras 3
NI - Nicaragua 3
AL - Albania 2
AT - Austria 2
BH - Bahrain 2
CL - Cile 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
LT - Lituania 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
CR - Costa Rica 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 9.942
Salva come PNG Salva come JPEG
Città #
Warsaw 1.173
Santa Clara 932
Ashburn 449
Fairfield 429
Singapore 292
Hong Kong 250
Chandler 232
Dublin 192
Seattle 174
Woodbridge 168
Houston 162
Cambridge 161
Wilmington 145
Seoul 132
Jacksonville 126
Milan 96
Beijing 95
San Jose 95
Ann Arbor 83
New York 71
Los Angeles 68
Lawrence 59
Altamura 57
Rome 51
Buffalo 48
Hefei 48
Princeton 47
Boston 45
Ho Chi Minh City 45
Lauterbourg 44
Moscow 41
Dallas 40
Council Bluffs 34
Mumbai 34
Boardman 33
Florence 33
Hanoi 33
Bern 31
San Diego 31
Helsinki 30
The Dalles 30
Melbourne 29
Naples 25
Munich 21
Medford 19
Orem 19
Phoenix 18
Shanghai 18
North Bergen 17
Bologna 16
Izmir 16
São Paulo 16
Bremen 14
Jakarta 14
Salerno 14
Dong Ket 13
Atlanta 12
Denver 12
London 12
Tokyo 12
Turku 12
Abidjan 11
Andover 11
Chicago 11
Kent 11
Da Nang 10
Frankfurt am Main 10
Palermo 10
Paris 10
Brooklyn 9
Falls Church 9
Haiphong 9
Norwalk 9
Toronto 9
Turin 9
Bari 8
Brussels 8
Clifton 8
San Francisco 8
Abuja 7
Figino 7
Guayaquil 7
Montreal 7
Redondo Beach 7
Brescia 6
Cagliari 6
Newark 6
Pune 6
Redwood City 6
Stockholm 6
Treviso 6
Abu Dhabi 5
Boydton 5
Chennai 5
Thái Bình 5
Venice 5
Amsterdam 4
Brasília 4
Cape Town 4
Hangzhou 4
Totale 6.956
Salva come PNG Salva come JPEG
Nome #
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 392
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 365
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 347
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 335
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 334
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 325
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 321
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 309
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 304
Nuovi target terapeutici nelle malattie mieloproliferativa croniche Ph negative 289
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. 276
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 274
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 224
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 218
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 216
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 201
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis 198
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 198
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 197
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 190
Chemotherapy-related nail toxicity 188
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. 187
Treatment options for essential thrombocythemia and polycythemia vera 186
Leukocytosis and risk stratification assessment in essential thrombocythemia. 180
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 174
Thrombosis in primary myelofibrosis: incidence and risk factors. 173
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 173
Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation 171
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 169
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 169
Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities? 166
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 165
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 160
Risk of second cancers in chronic myeloproliferative neoplasms. 153
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. 152
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. 152
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study 151
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 150
JAK2V617F allele burden and thrombosis: a direct comparison in Essential Thrombocythemia and Polycythemia Vera 148
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 148
Risk of second cancers in chronic myeloproliferative neoplasms 145
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study 145
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. 143
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 142
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 136
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. 130
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 114
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 102
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports 88
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM. 13
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction 11
Totale 9.997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.471
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022360 0 58 22 9 11 18 22 20 13 13 76 98
2022/2023974 88 174 47 98 76 157 116 58 89 7 28 36
2023/2024371 16 43 53 18 24 78 8 61 9 20 32 9
2024/20252.442 67 231 169 343 749 362 29 165 119 56 75 77
2025/20262.524 266 308 175 135 265 110 274 93 142 175 127 454
2026/2027213 195 18 0 0 0 0 0 0 0 0 0 0
Totale 9.997